<SEC-DOCUMENT>0001493152-22-020524.txt : 20220728
<SEC-HEADER>0001493152-22-020524.hdr.sgml : 20220728
<ACCEPTANCE-DATETIME>20220728163204
ACCESSION NUMBER:		0001493152-22-020524
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220728
DATE AS OF CHANGE:		20220728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257690
		FILM NUMBER:		221115648

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>form424b3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(3)<BR>
Registration No. 333-257690</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
Prospectus Supplement dated February 11, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>to
Prospectus dated July 9, 2021)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="image_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
BIOSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>400,000
Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Warrants to Purchase up to 400,000 Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement (&ldquo;Supplement&rdquo;) modifies, supersedes and supplements certain information contained in, and should be
read in conjunction with, that certain prospectus supplement filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
by Enveric Biosciences, Inc. (the &ldquo;Company&rdquo;), dated February 11, 2022 (the &ldquo;Original Prospectus Supplement&rdquo;),
and the accompanying base prospectus, dated July 9, 2021 (the &ldquo;Base Prospectus,&rdquo; and together with the Original Prospectus
Supplement, the &ldquo;Prospectus&rdquo;), related to an underwritten offering of an aggregate of 400,000 shares of the Company&rsquo;s
common stock, par value $0.01 per share (&ldquo;Common Stock&rdquo;) and warrants to purchase up to an aggregate of 400,000 shares of
Common Stock at an original exercise price of $27.50 per share and expiration date of February 15, 2027 (the &ldquo;Existing Warrants&rdquo;).
Some of the Existing Warrants have been amended as described below under &ldquo;Amendments to Existing Warrants.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock is listed on The Nasdaq Capital Market under the symbol &ldquo;ENVB.&rdquo; On July 21, 2022, the last reported sale price
of the Common Stock on The Nasdaq Capital Market was $7.82 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in this Supplement modifies and supersedes, in part, the information in the Prospectus. This Supplement is not
complete without, and may not be delivered or used except in connection with, the Prospectus. Any information that is modified or superseded
in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may amend or supplement the Prospectus from time to time by filing amendments or supplements as required. You should read the entire
Prospectus and any amendments or supplements carefully before you make an investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves risks. See &ldquo;Risk Factors&rdquo; on page S-9 of the Original Prospectus Supplement, page 5 of the Base
Prospectus and in the documents incorporated by reference into the Prospectus, including the risks described under &ldquo;Risk Factors&rdquo;
in our Annual Report on Form 10-K for the year ended December 31, 2021.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this Supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of 4:05 pm Eastern Time on July 14, 2022, we filed an amendment to our Amended and Restated Certificate of Incorporation to effect
a reverse stock split of the issued and outstanding shares of Common Stock, at a ratio of one share for fifty shares (the &ldquo;Reverse
Stock Split&rdquo;). All share and per share prices in this Supplement have been adjusted to reflect the Reverse Stock Split. However,
Common Stock share and per share amounts in certain of the documents incorporated by reference herein have not been adjusted to
give effect to the Reverse Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should carefully consider the risk factors set forth in or incorporated by reference into the Prospectus, as well as the other information
contained in or incorporated by reference into this Supplement and the Prospectus. This Supplement, the Prospectus and documents incorporated
therein by reference contain forward-looking statements regarding events, conditions, and financial trends that may affect our plan of
operation, business strategy, operating results, and financial position. You are cautioned that any forward-looking statements are not
guarantees of future performance and are subject to risks and uncertainties. Actual results may differ materially from those included
within the forward-looking statements as a result of various factors. Cautionary statements in the &ldquo;Risk Factors&rdquo; section
of the Original Prospectus Supplement, the Base Prospectus and the reports incorporated by reference therein identify important risks
and uncertainties affecting our future, which could cause actual results to differ materially from the forward-looking statements made
or included in this Supplement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENTS
TO EXISTING WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Supplement is being filed to disclose the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2022, in connection with a securities purchase agreement, dated as of July 22, 2022, entered into by the Company with an institutional
investor (the &ldquo;RD Purchase Agreement&rdquo;), the Company filed a prospectus supplement (the &ldquo;Registered Direct Prospectus
Supplement&rdquo;) and the accompanying base prospectus with the SEC under the Company&rsquo;s registration statement on Form S-3 (Registration
No. 333-257690). Pursuant to the RD Purchase Agreement and the Registered Direct Prospectus Supplement, the Company offered and sold
an aggregate of 116,500 shares of its Common Stock and pre-funded warrants to purchase up to 258,500 shares of Common Stock (the &ldquo;Registered
Direct Offering&rdquo;). Pursuant to the RD Purchase Agreement, the Company also offered and sold in a private placement to the institutional
investor in the Registered Direct Offering preferred investment options to purchase up to 375,000 shares of Common Stock, which have
an exercise price of $7.78 per share, are immediately exercisable, and will expire five and one-half years from the date of issuance.
The combined purchase price for one share of Common Stock and associated preferred investment option was $8.00 and for one pre-funded
warrant and associated preferred investment option was $7.9999. The Registered Direct Offering closed on July 26, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2022, concurrently with the closing of the Registered Direct Offering, the Company closed a private placement pursuant to a
securities purchase agreement, dated as of July 22, 2022, with two institutional investors, one of which investors participated in the
Registered Direct Offering, for the purchase and sale of 116,000 shares of Common Stock, pre-funded warrants to purchase up to 509,000
shares of Common Stock and preferred investment options to purchase up to 625,000 shares of Common Stock (the &ldquo;PIPE&rdquo;). The
combined purchase price for one share of Common Stock and associated preferred investment option was $8.00 and for one pre-funded warrant
and associated preferred investment option was $7.9999. The preferred investment options issued in the PIPE have an exercise price of
$7.78 per share, are immediately exercisable, and will expire five and one-half years from the date of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Registered Direct Offering and the PIPE, we entered into Warrant Amendment Agreements (the &ldquo;Warrant Amendment
Agreements&rdquo;) with the investors in the offerings to amend certain Existing Warrants to purchase up to an aggregate of 122,000 shares
of Common Stock held by the investors, in consideration for their purchase of approximately $8 million of our securities in the Registered
Direct Offering and the PIPE. Pursuant to the Warrant Amendment Agreements, effective upon the closing of the Registered Direct
Offering and the PIPE, such Existing Warrants held by the investors in the Registered Direct Offering and the PIPE were amended to reduce
the exercise price to $7.78 per share and to extend the term of such Existing Warrants to expire five and one-half years following the
closing of Registered Direct Offering and the PIPE. No changes have been made to the other Existing Warrants to purchase up to an aggregate
of 278,000 shares of Common Stock, which shares may be resold under the Prospectus, as amended by this Supplement.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this Prospectus Supplement is July 26, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F 34# 2(  A$! Q$!_\0
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MT445D>D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH<^E0J]7:YRN+3LSMOAXV?%40_V'_P#035;Q:^/%5_\ ]=?Z4_X<-GQ;"/\
MIF__ *":VM?\$:QJ.O7=W;B'RI7W+NDP<5S2:C4U[';&E.IA4H*_O/\ (XI7
MKIO#GAB[UIA*^8;0'YI".6]E]:V=#^'313+/JTJ.JG(@C)(/U/\ A7H$<211
MK'&JHBC 51@ 5G4K):1-L)ECD^:KHNQ7L-.M].MEM[:,(B^@Y)]2>YHJX**Y
M;GMJG%*R&CD4O(]ZY'4_$FI7.JS:/X=M(Y[J$#[1<S'$4)/;W/\ G!YQ%_9'
MCER6/B*TC)_A6V! _-:T5/2\FD9.NKM0BW;MM^)VF:,UQG]C^.?^AFMO_ 5?
M_B:/['\<_P#0S6W_ ("K_P#$T_9K^9?C_D'MY?R/\/\ ,[,=*3K[UGZ/!J-M
MIZQZG>)=W.XDRI&$&.PP*XJW\::Q9ZKJLE]9FZTBVO'@,T(&^  \9'<8[G\^
MU3&FY72Z#G7C!1<DU?\ #U/1J6J.G:G9ZM:)=65PDT3=&0]#Z$=C[&KO:H::
MT9LFFKH*.#29KFO"6KW>J_VQ]K=6^S:A)!%A0,(,8'O346TWV)E-*2B^M_P.
MEQS1BN3FUV\TGQ?]@U0H-.O<?8YPN C]T8^Y_F/7CK<T2BXVOU"$U*Z70***
MH:KJ=MI&G3WUT^R*)<GU)[ >Y/%"3;LAMJ*NR]WHSTXKG_"]WJ^HZ=)J&IJD
M:W+[[> +@QQ]LGOGK_\ KP(=>\2S6%[#I.EVGVW59QO6,G"1K_><^GY?RS7(
M[V,_:Q4%-Z)_?]QT^:,UQ8TWQW, TFNV-N3UCB@# ?B5I?['\<_]#-;?^ J_
M_$U7LU_,OQ_R)]O+^1_A_F=G17&?V-XX_P"AFMO_  %7_P")K8T2RUNU2;^V
M-3BO&8CR_+A";.N>F,YX_*IE!)7YDRH592=G%K[C;I/I7#ZC>>(K_P 97>DZ
M7JD=E#! DGS0J^<XSU!]:F_L?QOG_D9K;_P$7_"G[+17DD1]8;ORP;L[=#L\
MT9KC?['\;_\ 0SVW_@(O^%)_97CE#E?$5I(1_"]L #^(6G[-?S+\?\A^WE_(
M_P /\SLB,FC%<WX9UZZU&:\T[4X$@U*S8"54/R,#T9?\^E U>[/Q".D;U^Q_
MV?Y^W:,[]^,YZ]*GV;NUVU*5>#BI+J[?,Z6DZUB>(_$,>@VD;"%[B[G?R[>W
M3[TC?X=/S%8JV_CR_42OJ%AIV[I"D7F%1[D@\_C1&FVKMV7F$ZRC+E2;?D=M
MFC-<9_8_CG_H9K;_ ,!5_P#B:/['\<_]#-;?^ J__$U7LU_,OQ_R)]O+^1_A
M_F=B/PIU<WHUAXFMKWS-5UF&ZM]I'EI %.>QR *Z3M6<E9[W-82<E=IKU/#/
MB:V/&DX_Z9I_Z"*Y-7KI_B@V/&]P/^F4?_H(KDX%DGE2*)&>1SA549)/H!7K
M4E^[7H?,XE?OI^K.W^&K9\7P_P#7-_\ T$U[8*X/P!X-DT-#J-_@7DJ;5C'/
ME*>3GWX'TKO.OXUYU>2E/0]S TI4Z-I;O4=1116)VA1110!Y=X=\1OH\^LHF
MB:E>M)J4SF6VAWKUZ9]>I_&MW_A/)_\ H5==_P# 8U2L-13P;KNI6.J@QV=]
M<M=6UUM)3+=5/IC _+W%=<FO:1*@=-4LV4\@BX7_ !KIJ-7ORWOUNSSJ"ER\
MO/9J^EEIKYG/?\)Y/_T*NN_^ QI?^$\F_P"A5UW_ ,!C71?VUI7_ $$[/_O^
MO^-']M:5_P!!.S_[_K_C47C_ "?F;6G_ ,_/P19MYC<6T4QC>(R(&,<@PRY&
M<$>HKD_ X#7WB8$ @ZI*"#]376P7$-S$)8)HY8SP&C8,/S%<IX%_X_O$W_85
ME_G2C\,OE^953^)#Y_D-U'PA/8W;ZGX7G%E=GE[8_P"IF]L=OY?3K5G1O&$5
MW=G3-6@;3M57CR9?NR>Z'OGT_+-=2?6LK6M!T_7[7R+^ /C[D@X=#Z@_Y%"F
MI*T_OZ_\$'2E!\U+3RZ/_)FKVKC/ /\ S,7&3_:\W]*KB]UWP60FH"35=%'2
MZ09F@'^T.X_SGM4GPYGCNK?7+B%MT<NJ2NAQC*D BJY7&G)[K3\S/VBG5@FK
M-7NGZ?B='KNB6_B#2I;&Y& W*.!S&XZ,*Q_">M7+2RZ%K!VZK9<9/_+>/LX]
M>V?P/K769X]:Y;Q;H5Q>)#J^EG9J]C\T) _UB]T/KWQ]2.]1"2:Y);?DS6M%
MQ?M(;K==U_FNAT[,%4DD #GGM7"(#X[U_P UL_\ "/:=)\@[74H[^ZC^7U.*
MMQXDN/&D-IHFE"2WDN$SJ,A4_N$!PRCUS_4#N<=YIUC;:980V5K&(X85VJ/Z
MGW/6JLZ2U^+\C/F^L.T?A6_F^WHNI;P!Q7FIUM]'^(NO2#2[V_=DB1?LL>\Q
MC:#SZ \?E7I=<)J-P?"GC2XU>YB=M+U&-$EF09\F11@9'I@?K[446KM6O=#Q
M2:47>UGOVT+'_">3_P#0JZ[_ . QH_X3R?\ Z%77?_ 8UNP>(M&N(Q)%JUFR
MG_ILH/Y$\5-_;6E?]!.S_P"_Z_XT[Q_D_,24W_R\_!'.?\)Y/_T*NN_^ QKI
M-)U!M4T^.Z:TGM"^?W-PNUUP<<BD_MK2O^@G9_\ ?]?\:GM[RUNPQMKF&8+]
MXQN&Q]<5G.UM(V^\UIW3UG?[C@KW67T?XDZC,FFWE\6M8UV6J;BOW3D^U:/_
M  GEQ_T*NN?^ YI^G_\ )4M6_P"O*/\ ]EKL?TK6<H*UXWT75F%*%1\SC*RN
M^B[G&?\ ">W'_0JZY_X#FH)_B,\#Q1/X;U2.6=MD2S)Y>]O0$UW0Q6-XET./
MQ!HTMFS!)?OQ2?W''0_T/L34QG3;UCIZLN=.LHMQG=^B,WPMI>HIJ&H:YJZI
M#=WY4+ AR(D48 )]>GY>]0#GXO-_V"/_ &I5WPAKDNJ:<]M>C;J=BWDW*'J2
M. WXX_/-4E_Y*Z?^P1_[4JE?FE?LR'R\D''NO6_6XFL 2?$WP^K %5@F90>Q
MVMS^@KL^]<;XOBNM.UC2_$EO ]PED6CN(D&6\MAC</ID_I[UKV/BO0M0@\R'
M5+;D9*O($8?4'!J)IRC%K:QI3E&%2<9.S;O\K(W*/PK/_MK2O^@E9_\ ?]?\
M:/[:TK_H)6?_ '_7_&L^5]C?VD>Z^\T*6J<&I65T_EV]Y;S/C.V.56./H#5O
M-)JVY2:>QXAX]TF^UKXD2V>GP/+,\4?3HHVCDGL/>O0/"/@6R\,P":3;<Z@P
M^:8CA/9/3Z]3^E=847<6"C<1@G')%*0>:VE7E*"@M$<T,+"-1U'JV_N'T445
MB=04444 %%%% %:XMK>\A,%Q#'-$W5)%# _@:QF\$^'&8DZ1 /ID#\@:Q6U:
MYFO]8$WBA--%M<&.&)DB(VA0<X8;CR372^'[R[O]!L[J^B\JYE3,B8QWX.#T
MR,''O6K4H*Z9S*5.J[.-_6WH5/\ A!O#7_0)A_[Z;_&C_A!O#7_0)A_[Z;_&
MN@K$TB_N;K7-;MI9-T5M-&D2[0-H,88_7DTE.HTWS/3S*=*DFERK7R-#3],L
M]+MOLUE D,62VU/4]Z=:Z?:V;3M;P)$9Y#+*5&-[GJ35DGIS6#K6HW8U"STG
M362.ZN5>1IW7<(8UQDA>Y)( [5*NWN7+E@D[;;&]1QBN4N)=7\.RV]Q=:B=1
ML9)4AE$D2H\18X#*5P",D9!KJQ2:MJ.$^:ZM9H0J",$9!ZBJMEIMGIB2)96L
M4"R.9'6-< L>]+?RS6^GW,UM%YTZ1,T<?]]@"0/Q-<MX?O-2U%;2YAUV*[E)
M'VVRE14\K/W@H4;@5/'/!IQ3:;OH3.<8R2M=G:44"JU]=QV%A<7<N?+@B:5\
M=<*,G^52M31NRNQEKIUG933S6UO'%)<-OE95P7/J?UJY7*6EOXCU.SBOSJZ6
M<DR"1+5+=7C0$9"L3\Q.,9((]JW=*EO)M/B;4+=8+OD2(C;ER#C(/H>OXU4E
M;5NYG3DGHE9%ZF21I,C)(JLC#!4C((I]8>G7]S/XHUBSD?-O;QV[1+M^Z6#;
MN>_05*3=WV+E))I/J,D\%>')G+OI%N">NT%1^0.*;_P@WAK_ *!,/_?3?XUT
M-<QXFU&XM-1TFWCU$6$%R\HFF(3@*F1RXP.>/QK2,YMV4F8SITHKF<5]Q+_P
M@WAK_H$PC_@3?XU?TS0]-T82?V?:1V_FXW[<Y;&<=?J?SHTC)M2W]J_VDI;B
M;Y,#CI\@ _\ UUI$TI3D]&VRH4X*THQ2962PM8[^2^2!!=2($>4#EE'059YS
M7'ZSX@O=*\6)'@2:7':++<J -T8:0KY@[D#C(],UJ1:A/+XQ>R64-:#3TG50
M!RQD89S] *'!VN^P1JQNTN]O^";M%%8WB#4[C3[>WBLT5KR[G6WAW_=4D$EF
M]@ 3413;LC24E%79>BT^TAO9KR*W1;F8 22 <N!TS2_8+7^T?[0^SI]K\ORO
M-Q\VS.<?G6&]GXCL EQ%J8U,AAYEM+ D>Y<\[&&,$>^:Z4=.:IW76Y,&GHXV
M%P#UK#N_">@WDIEFTFV,A.2RIM)^N,9K;)X)KB?#&HW.JVMG<W7B4?:9')>S
M A&<,1MQC=R!3AS6;3L35<6U&2O?T-7_ (0?PU_T"8?^^F_QH_X0?PU_T"8?
M^^F_QKH>N#69K]W=66A7ES8PF:ZCC+1IC.3].^.N/:FIS;MS/[Q2HTDFW%:>
M1'IWAK1M*N?M-C810S8*[P23@_4UL5RVB37EW-!<6NOQ:G:.I^T+(BJ\;8X*
MA0,<]5:NIJ:E[ZNY5+EY?=5D+1114FH4444 %%%% !1110!Y;<>(['1M>URS
MNM+2\DFO"X+!<8*J,'()[?K7<>&K*XL/#UG!<RB255))4D@ DD*">< $#\**
M*Z:R2@OZZ'GX5WJ2\K_F;-<[H2E?$OB0\<W$1_\ (2T45A'X7_74ZY_%'U_0
MZ*N<\06MQ;W5KK=F8S/9HZ212,566-L9&0#@@@$<444Z>Z"M\#,33]:;Q^T4
M4, M;"VF26?S'R\A4[E4 # &0,G.:[[N***JLK-)&>';DKO<AF$C1.(G"2;2
M%8C(!QP<5YT=0;7?$5AIK6L,&LVDXDFO8S@%4/S!>,G<.QXHHIT5H_0C%/6*
M_K<]+'2JU]:1WUA<6DN?*GC:)\=<,,'^=%%8HZI:Q.%/BZ[\/3V_ARYM8KF_
M 6*"=9"L;CHI<8R#@#(&:[/2DNXM.A6_N%N+HC+R(FT9)Z >@SC\***Z*L4H
MIG'0G)S:;V-"N>TM,>-/$#<<Q6OZ*]%%8QV?I^ITU/BCZ_H=":XOQQ=Q:;=Z
M+?W$"SP0RR[XCCYLI@=1CJ<T455+62(Q3M3;7]:FMX6UNUUS3Y9K6T^S)'+L
M*8 R< YX^M;N.M%%*HK2=BZ+;A%LYHPK+\0)A(JM&^E*I#<Y_>'((]*H>'M,
METSQI=VQF$EO#9JEMG.Y(RY8*3WP20/;%%%:)Z/T,&ES+_$SM:Q?$6G37MK!
M/:2)'=V4PN(B^=K$ @JV.<$$BBBL8NTCHJJ\&<YI_C&\\3W1T_3(5L9T;]]/
M(X?:H/.P;<$GWQ7=D=Z**UJI1E9'/A)RJ1O)]0/?Z5YEX2\1V-B-/T=]-5[S
MS3']H 7JSGG.,]Z**JDDXRN&(DXU(V/3^U5KU;EK*9;1T2X*GRVD&5#=LCTH
MHKG1U2^$X/3-3B\1>++8VUE'9WU@S->SJV/-7!4H,#Y@3@_-C&*]$]***VK*
=S278Y\([QDWW'4445B=04444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
